-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
Bi/Multispecifics
Tackling the challenge of identifying platforms that deliver diverse, functional, and clinically rel
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Clients’ demands for more complex formats for bispecific and multispecific antibodies continue to cr
...
-
ADC Cytotoxic Payload
What causes resistance to ADCs with standard-of-care payloads in patients? How should we choose betw
...
-
ADC Linker Design & Conjugation Technologies
-
ADC Linker Design & Conjugation Technologies
What are the toxicities associated with traditional linker-platforms Next-generation linkers to bal
...
-
AI & Machine Learning
Why does sequence-to-function prediction remain noisy and context-dependent? Why do naïve repertoire
...
-
AI & Machine Learning
Recent advances in transient gene expression and AI-assisted antibody engineering have enabled rapid
...
-
Formats & Scaffolds
There are many parameters to optimize, especially when you get to 3+ binding moieties. which knobs a
...
-
ADC Cytotoxic Payload
What resistance mechanisms are we still missing beyond drug export and target mutation? Can we mov
...
-
Formats & Scaffolds
In silico and in vitro immunogenicity assessment as a de-risking strategy Approaches to mitigate the
...
-
ADC Linker Design & Conjugation Technologies
-
ADC Linker Design & Conjugation Technologies
How can we balance payload release with drug product (DP) stability? What is the bystander effect,
...
-
AI & Machine Learning
How can AI/ML models effectively integrate the intricate relationships between protein sequence, str
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Aureka Biotechnologies is a pioneer in the next generation of antibody discovery and engineering via
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Optimizing protein therapeutics for clinical success: How can incorporating developability assessmen
...
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
Is there a need for novel targets that can differentiate based on biology and overcome target-depend
...
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
The antibody response to vaccination and infection is key to immune defense and human antibody thera
...
-
Formats & Scaffolds
Artificial intelligence (AI) is transforming antibody discovery and engineering. Ailux's platform sy
...
-
Bi/Multispecifics
Efficient bispecific antibody (bsAb) production requires precise assembly of multiple chains. Combin
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
The PioneerTM Antibody Discovery Platform is Bio-Rad’s biotherapeutic antibody generation service, c
...
-
Formats & Scaffolds
How can cost and efficiency be balanced in the discovery of optimal SDAbs for use in multifunctional
...
-
Bi/Multispecifics
How is cytokine release syndrome (CRS) managed, and what is the role of Tocilizumab in its treatment
...
-
Lead Identification & Optimization
-
Lead Identification & Optimization
Can large-scale screening platforms capture functional and developability complexity, or are we miss
...
-
Target Selection & Mechanisms of Action
-
Target Selection & Mechanisms of Action
How has epitope or conformation-specific binding bias improved the therapeutic index of antibody dru
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Drinks-Canape Reception
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Afternoon Refreshments
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Networking Lunch
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Morning Refreshments
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
1-2-1 Meetings / Networking Break
-
Bi/Multispecifics
What are the novel mechanisms of action? Is there an optimal format? What are the challenges in deve
...
-
Target Selection and Mechanisms of Action
-
Target Selection & Mechanisms of Action
How do we pair targets with the suitable MOA for the specific cell type and disease indication selec
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut
...
-
-
Bi/Multispecifics
-
Formats & Scaffolds
-
Target Selection & Mechanisms of Action
-
AI & Machine Learning
-
ADC Linker Design & Conjugation Technologies
-
ADC Cytotoxic Payload
-
Lead Identification & Optimization
Registration
)
Clients’ demands for more complex formats for bispecific and multispecific antibodies continue to cr ...
)
Aureka Biotechnologies is a pioneer in the next generation of antibody discovery and engineering via ...
)
We will explore some of the cutting-edge advancements in our antibody discovery and engineering appr ...)
Off-target binding is a significant hurdle in the development of antibody-based therapies, contribut ...
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)